ICU MEDICAL, INC. (NASDAQ:ICUI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In accordance with the Company's director retirement policy, Mr. Joseph R. Saucedo notified the Board that he would not stand for reelection as a director at the Company's 2018 Annual Meeting of Shareholders. Accordingly, Mr. Saucedo's tenure as a director ended when his current term expired at our May 15, 2018 Annual Meeting. Mr. Saucedo's decision to retire was not in connection with a disagreement relating to the Company's operations, policies or practices.
The disclosure set forth under Proposal 1 in Item 5.07 of this Form 8-K is incorporated herein by reference.
Item 5.07Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, the following proposals were voted on by the Company’s stockholders, as set forth below:
Proposal 1.Election of directors.
|
Name of Nominee |
Votes For |
Withheld |
Broker Non-Votes |
|
Vivek Jain |
16,843,791 |
709,182 |
1,562,057 |
|
George A. Lopez, M.D. |
16,123,661 |
1,429,312 |
1,562,057 |
|
Robert S. Swinney, M.D. |
16,974,675 |
578,298 |
1,562,057 |
|
David C. Greenberg |
16,965,002 |
587,971 |
1,562,057 |
|
Elisha W. Finney |
14,198,787 |
3,354,186 |
1,562,057 |
|
Douglas E. Giordano |
16,706,385 |
846,588 |
1,562,057 |
|
David F. Hoffmeister |
17,442,964 |
110,009 |
1,562,057 |
|
Donald M. Abbey |
17,527,584 |
25,389 |
1,562,057 |
The Company’s stockholders elected each of the director nominees to serve as a director for a term of one year until the 2019 annual meeting of stockholders and until their respective successors are elected and qualified.
Proposal 2. Ratification of the appointment of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018.
|
Votes For |
Votes Against |
Abstain |
Broker Non-Votes |
|
17,077,895 |
2,015,639 |
21,496 |
The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.
Proposal 3.Approve the advisory vote on the Company’s named executive officer compensation.
|
Votes For |
Votes Against |
Abstain |
Broker Non-Votes |
|
17,261,947 |
260,471 |
30,555 |
1,562,057 |
The Company’s stockholders approved on an advisory basis the Company’s named executive compensation.
About ICU MEDICAL, INC. (NASDAQ:ICUI)
ICU Medical, Inc. is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. It operates through the segment, which is engaged in the development, manufacturing and sale of medical technologies used in infusion therapy, critical care and oncology applications. Its Infusion Therapy products include MicroClave and MicroClave Clear, Neutron, NanoClave, Clave and SwabCap. Its Critical Care products include Hemodynamic Monitoring Systems, Closed Blood Sampling and Conservation Systems, and Other Critical Care Products and Accessories. Its Oncology products include ChemoLock CSTD and components, ChemoClave CSTD and components and Diana hazardous drug compounding system.